Effects of GLP-1 receptor agonists on gut microbiota during treatment in type 2 diabetes mellitus

Correlation between FOXC2 gene polymorphisms and intestinal microbiota in Dai and Han nationalities in Yunnan

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063198

Enrollment

Unknown

Registered

2022-09-01

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Experimental group:GLP-1 receptor agonists for the treatment of type 2 diabetes

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Good health condition and independent living ability; 2. All participants participated in the study voluntarily and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Digestive tract diseases: broken gut syndrome, small intestine dysfunction, chronic liver disease, inflammatory enteritis, digestive tract ulcers long-term treatment with acid suppressive drugs and digestive tract operations; 2. Endocrine diseases: severe thyroid and parathyroidism, hypopituitarism, hypogonadism, growth hormone deficiency, hyperprolactinemia, etc.; 3. Drugs: long-term use of hormones, antibiotics, metformin, etc.; 4. Other serious heart, brain and kidney diseases; 5. Patients who are breastfeeding.

Design outcomes

Primary

Measure	Time frame
Gut microbiota diversity;	—

Countries

China

Contacts

Public ContactLiang Lei

Department of Endocrinology, the First Affiliated Hospital of Kunming Medical University

Chinalianglei@outlook.com+86 18815605487

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026